RobertWesolowskiMD

Oncology • Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Wesolowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wesolowski's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-6529

Fax+1 614-293-9429

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010
Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004

Certifications & Licensure

OH State Medical License 2004 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
Completed
Phase 4
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
Completed
Phase 1
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
COMPLETED
PHASE1, PHASE2
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors Start of enrollment: 2018 Jul 18
Completed
Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Start of enrollment: 2019 Nov 14
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

HSR25-154: Treatment Patterns and Prognosis of Patients With HER2-Negative Early Breast Cancer and Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2.
Vishnu Prasath, Andrea Riner, Joanne Kim, Akia Clark, Brandon Slover
Journal of the National Comprehensive Cancer Network. 2025-03-28
The role of oxytocin in mediating the relationships between social factors and chemotherapy-associated cognitive decline in female patients with breast cancer.
Melina M Seng, Seth Adarkwah Yiadom, Lauren D Otto-Dobos, Sagar D Sardesai, Nicole O Williams
Psychoneuroendocrinology. 2025-03-15
CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications.
Sayan Mullick Chowdhury, Feng Hong, Christian Rolfo, Zihai Li, Kai He
Biology. 2025-02-18

Journal Articles

Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint Inhibitors
Robert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences

Press Mentions

Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024
Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
Join now to see all

Grant Support

Training Hematology and Oncology Fellows in Clinical ResearchOHIO STATE UNIVERSITY2020–2025